Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors | Zendy

Jonathan Strosberg | Zendy; Ghassan ElHaddad | Zendy; Edward M. Wolin | Zendy; Andrew Hendifar | Zendy; James C. Yao | Zendy; Beth Chasen | Zendy; Erik Mittra | Zendy; Pamela L. Kunz | Zendy; Matthew H. Kulke | Zendy; Heather A. Jacene | Zendy; David Bushnell | Zendy; Thomas M. O’Dorisio | Zendy; Richard P. Baum | Zendy; Harshad Kulkarni | Zendy; Martyn Caplin | Zendy; Rachida Lebtahi | Zendy; Timothy J. Hobday | Zendy; Ebrahim S. Delpassand | Zendy; Eric Van Cutsem | Zendy; Al B. Benson | Zendy; Rajaventhan Srirajaskanthan | Zendy; Marianne Pavel | Zendy; Jaime Font de Mora | Zendy; Jordan Berlin | Zendy; Enrique Grande | Zendy; Nicholas S. Reed | Zendy; Ettore Seregni | Zendy; Kjell Öberg | Zendy; Maribel Lopera Sierra | Zendy; Paola Santoro | Zendy; Thomas Thevenet | Zendy; Jack L. Erion | Zendy; Philippe Ruszniewski | Zendy; Dik J. Kwekkeboom | Zendy; Eric P. Krenning | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors

Author(s) -

Jonathan Strosberg,

Ghassan ElHaddad,

Edward M. Wolin,

Andrew Hendifar,

James C. Yao,

Beth Chasen,

Erik Mittra,

Pamela L. Kunz,

Matthew H. Kulke,

Heather A. Jacene,

David Bushnell,

Thomas M. O’Dorisio,

Richard P. Baum,

Harshad Kulkarni,

Martyn Caplin,

Rachida Lebtahi,

Timothy J. Hobday,

Ebrahim S. Delpassand,

Eric Van Cutsem,

Al B. Benson,

Rajaventhan Srirajaskanthan,

Marianne Pavel,

Jaime Font de Mora,

Jordan Berlin,

Enrique Grande,

Nicholas S. Reed,

Ettore Seregni,

Kjell Öberg,

Maribel Lopera Sierra,

Paola Santoro,

Thomas Thevenet,

Jack L. Erion,

Philippe Ruszniewski,

Dik J. Kwekkeboom,

Eric P. Krenning

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1607427

Subject(s) - midgut , neuroendocrine tumors , medicine , somatostatin receptor , somatostatin , radionuclide therapy , somatostatin receptor 2 , lutetium , cancer research , oncology , pathology , endocrinology , biology , chemistry , botany , organic chemistry , larva , yttrium , oxide

Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 ( 177 Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research